Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Palvella Therapeutics, Inc.
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must be 6 years or older
Diagnosed with Microcystic Lymphatic Malformations
Able and willing to comply with all protocol-required activities
Willing and able to provide written informed consent
You may not be if
Any significant concurrent condition that could adversely affect participation.
Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022
Patient's deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities.
Clareo Health | Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
